Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Other EventsItem 8.01 Other Events.
Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Other Events
On May 18, 2017, Bioptix, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company had regained compliance with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605. The compliance was regained following the appointment of Andrew Kaplan to the Company’s Board of Directors and Audit Committee as previously disclosed on May 8, 2017. Nasdaq Listing Rule 5605 requires that the Company’s audit committee be comprised of at least three independent directors. The Company’s non-compliance resulted from the April 6, 2017 appointment of Mr. Michael M. Beeghley, the Company’s current Chairman and then member of the audit committee, to the position of Chief Executive Officer. Mr. Beeghley’s appointment to the position of Chief Executive Officer resulted in his no longer being independent, resulting in the audit committee thereupon being comprised of two independent members.
About Bioptix, Inc. (NASDAQ:BIOP)
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions. Bioptix, Inc. (NASDAQ:BIOP) Recent Trading Information
Bioptix, Inc. (NASDAQ:BIOP) closed its last trading session up +0.17 at 3.59 with 13,455 shares trading hands.
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions. Bioptix, Inc. (NASDAQ:BIOP) Recent Trading Information
Bioptix, Inc. (NASDAQ:BIOP) closed its last trading session up +0.17 at 3.59 with 13,455 shares trading hands.